Researchers evaluated the relationship between device-monitored, VILPA and cancer
Filament Health Announces Warrant Exercise and Note Conversion by Negev Capital and Concurrent Private Placement of Common Shares to Benjamin Lightburn, Chief Executive Officer | Psychedelic Invest
VANCOUVER, BC, June 3, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today